Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector ...

On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 ...

Calcium+Company, a 2025 MM+M Agency 100 honoree, named Susan Goldstein as an EVP who has joined the Protein team. Bobby ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

MarioGuti Most major stock indexes across the globe ended the week higher, as renewed optimism around US-China trade talks ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved ...

We have just scratched the surface as to how we embrace these disruptive technologies to achieve our ambition of transforming the practice of medicine”, Paul Hudson, CEO of Sanofi. In under two ...